BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Avila Therapeutics 

100 Beaver Street

Waltham  Massachusetts    U.S.A.
Phone: 781-891-0086 Fax: 781-891-0069


SEARCH JOBS


Industry
Biotechnology






 Company News
Celgene Corporation (CELG) Completes Acquisition of Avila Therapeutics 3/8/2012 6:47:19 AM    More...
Celgene (CELG) Acquisition of The Leukemia & Lymphoma Society Partner, Avila Therapeutics, Significant Advance for Novel Blood Cancer Therapy 1/27/2012 10:59:41 AM    More...
Celgene (CELG) to Acquire Avila Therapeutics for Up to $925 Million 1/26/2012 7:10:22 AM    More...
Avila Therapeutics Announces FDA Allowance of Partner Clovis Oncology (CLVS)’s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor, Triggers $4 Million Milestone Payment to Avila 1/20/2012 7:17:05 AM    More...
Avila Therapeutics to Present at J.P. Morgan Healthcare Conference 1/3/2012 6:56:45 AM    More...
Avila Therapeutics Presents Data on AVL-292, a Selective Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of B Cell Cancers at the 2011 American Society of Hematology Annual Meeting 12/12/2011 11:10:23 AM    More...
Avila Therapeutics to Present at the 2011American Society of Hematology Annual Meeting 12/5/2011 6:28:14 AM    More...
Avila Therapeutics Presents Clinical and Preclinical Data on AVL-292 Showing Potential for the Treatment of Autoimmune Disease at the 2011 American College of Rheumatology Annual Scientific Meeting 11/8/2011 7:21:05 AM    More...
Avila Therapeutics to Present at Lazard Capital Markets 8th Annual Healthcare Conference 11/7/2011 4:21:42 PM    More...
Avila Therapeutics Completes Dosing of First Patient Cohort in Phase 1b Clinical Study of AVL-292, a Selective Bruton's Tyrosine Kinase Inhibitor for the Treatment of B Cell Cancers 9/14/2011 9:04:09 AM    More...
12345

//-->